Alzamend Neuro director Lynne McGrath dies
Alzamend Neuro, Inc., a Delaware corporation listed on the Nasdaq Capital Market under the symbol ALZN, reported that director Lynne Fahey McGrath, M.P.H., Ph.D. passed away on July 20, 2026.
Rhea-AI Filing Summary
Alzamend Neuro, Inc., a Delaware corporation listed on the Nasdaq Capital Market under the symbol ALZN, reported that director Lynne Fahey McGrath, M.P.H., Ph.D. passed away on July 20, 2026. She had served on the Board of Directors since the company’s initial public offering in June 2021.
Board Chairman William B. Horne described her “sudden passing” as a profound loss, highlighting her passion for the company, focus on corporate governance, generosity with her time, and significant insights and biopharmaceutical knowledge. He emphasized that she was regarded as irreplaceable and extended condolences to her family, friends, and all those whose lives she touched.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Date of director's death: July 20, 2026
Board service since: June 2021
Commission File Number: 001-40483
+1 more
4 metrics
Date of director's death
July 20, 2026
Date on which director Lynne Fahey McGrath passed away
Board service since
June 2021
Lynne Fahey McGrath served on the Board since the initial public offering in June 2021
Commission File Number
001-40483
SEC Commission File Number for Alzamend Neuro, Inc.
Common stock par value
$0.0001 per share
Par value of Alzamend Neuro, Inc. common stock
Key Terms
Emerging growth company, Inline XBRL, Regulation S-T, corporate governance
4 terms
Emerging growth company regulatory
"The company is identified as an Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"the cover page is formatted in Inline XBRL"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Regulation S-T regulatory
"Pursuant to Rule 406 of Regulation S-T"
corporate governance financial
"she was thoughtful in her approach to corporate governance"
Corporate governance is the system of rules, roles and oversight that determines how a company is directed and controlled, including the responsibilities of its board, executives and shareholders. Like the steering wheel and map for a car trip, it shapes decisions, sets checks on power and defines who can hold leaders accountable; strong governance reduces risk, builds trust and helps investors judge whether a company is likely to protect capital and deliver reliable returns.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alzamend Neuro (ALZN) report about its Board of Directors?
Alzamend Neuro (ALZN) reported that director Lynne Fahey McGrath, M.P.H., Ph.D. passed away on July 20, 2026. She had served on the Board of Directors since the company’s June 2021 initial public offering.
Who was Lynne Fahey McGrath in relation to Alzamend Neuro (ALZN)?
Lynne Fahey McGrath, M.P.H., Ph.D., was a director of Alzamend Neuro (ALZN) and a Board member since June 2021. The Board Chairman highlighted her passion for the company, corporate governance focus, and biopharmaceutical knowledge.
When did Lynne Fahey McGrath join the Alzamend Neuro (ALZN) board?
Lynne Fahey McGrath joined the Alzamend Neuro (ALZN) Board of Directors at the time of its initial public offering in June 2021. She served continuously as a director from that IPO until her death on July 20, 2026.
How did Alzamend Neuro (ALZN) describe Lynne McGrath’s contributions?
Alzamend Neuro (ALZN) described Lynne McGrath as a passionate director who prioritized the company’s needs, was thoughtful about corporate governance, unselfish with her time, and provided significant biopharmaceutical insights to the Board.
What comments did Alzamend Neuro’s (ALZN) Board Chairman make about Lynne McGrath?
Board Chairman William B. Horne expressed profound sadness over her “sudden passing” and called her one of the few irreplaceable people. He emphasized that she would be deeply missed as both a respected colleague and a friend, extending condolences to her family and friends.
On which exchange is Alzamend Neuro (ALZN) listed and what is its ticker?
Alzamend Neuro is listed on The Nasdaq Capital Market under the trading symbol ALZN. Its common stock has a par value of $0.0001 per share, as stated in the company’s securities information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
